The report provides comprehensive information on the
therapeutics under development by Lupin
Limited, complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
report also covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and the dormant and discontinued
projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619241-lupin-limited-product-pipeline-review-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the pipeline therapeutic
landscape of Lupin Limited
- The report provides overview of Lupin Limited including
its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report assesses Lupin Limited’s pipeline therapeutics
based on drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type
- The report features Lupin Limited’s out-licensed and
partnered product portfolio and summarizes its dormant and discontinued
projects
Reasons to buy
- Evaluate Lupin Limited’s strategic position with total
access to detailed information on its product pipeline
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Lupin Limited
- Identify potential new clients or partners in the target
demographic
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Lupin Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
Table of
Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Lupin Limited Snapshot 6
Lupin Limited Overview 6
Key Information 6
Key Facts 6
Lupin Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Lupin Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Lupin Limited - Pipeline Products Glance 12
Lupin Limited - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Lupin Limited - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Lupin Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Lupin Limited - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Lupin Limited - Drug Profiles 18
Biosimilar for Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
etanercept biosimilar 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
LND-101001 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
LNP-1892 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule for Colon and Lung Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Agonize CaSR for Chronic Kidney Disease
and Primary Hyperparathyroidism 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Access Report @ https://www.wiseguyreports.com/reports/619241-lupin-limited-product-pipeline-review-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment